http://www.reuters.com/article/2012/03/28/us-science-cancer-idU A former researcher at Amgen Inc has found that many basic studies on cancer -- a high proportion of them from university labs -- are unreliable, with grim consequences for producing new medicines in the future. Of 47 cancer projects at Bayer during 2011, less than one-quarter could reproduce previously reported findings, despite the efforts of three or four scientists working full time for up to a year. Bayer dropped the projects.
C*d
4 楼
Such houses are usually sold as it. Otherwise very similar to normal house.
For the industry people: if you are getting something for free (or nearly free), you can't complain too much about the quality. It's just bad for the public who funded the research.
NIST and ABRF used to have some studies in which they sent out unknown samples to some core labs and ask back the raw data and they will do the data processing to check the results between different labs. My thought is that since in all NIH grants, PIs propose some experiments. NIH or NIST can ask PI to spike in their "secret" internal standard and check the results. Not applicable to all experiments but should be doable for a lot of modern technologies.
【在 n*********4 的大作中提到】 : http://www.reuters.com/article/2012/03/28/us-science-cancer-idU : A former researcher at Amgen Inc has found that many basic studies on cancer : -- a high proportion of them from university labs -- are unreliable, with : grim consequences for producing new medicines in the future. : Of 47 cancer projects at Bayer during 2011, less than one-quarter could : reproduce previously reported findings, despite the efforts of three or four : scientists working full time for up to a year. Bayer dropped the projects.
K*S
33 楼
So ppl in academic can reproduce more than ppl in industry do?
【在 M*P 的大作中提到】 : 工业界的人也未必都干净。他们说75%的不能重复,估计至少也有一半不能重复的是他 : 们自己有问题。 : 工业界拿那么高薪水,整天养尊处优,朝九晚五也不会被开除,做得出东西才奇怪。作 : 不出来,反而出来指责学术界,其实是找个借口,掩盖他们水平不够。 : 现在很多工业界的东西直接外包,一是便宜,另外就是工业界发现他们体制内没有一个 : 激励自己科学家努力创新的机制。 : : cancer : four
l*s
34 楼
I would say yes. Clinical trials are exorbitantly expensive, drug companies have incentive to audit internal data.
【在 K******S 的大作中提到】 : So ppl in academic can reproduce more than ppl in industry do?